Combined analysis of CSF βA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data
作者： C. Briani , S. Ruggero , M. Naccarato , A. Cagnin , G. L. Ricchieri
关键词:
摘要: Neuropathological hallmarks of Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles, containing betaA(42) peptide tau protein, respectively. Amyloid contain also glycosaminoglycans (GAGs). Whereas cerebrospinal fluid (CSF) levels protein have been demonstrated as potential markers (AD), no data available for GAGs. We determined (Elisa) CSF levels, well serum antibodies to GAGs in 9 AD patients, the values were analyzed relation age severity disease. Beta-A42 significantly reduced increased, respectively, patients when compared controls, but they did not correlate with Despite their role amyloidogenesis, we find evidence use diagnostic marker AD.
springer.com
elsevier.com
sci-hub.se 参考文章(9)
R. Motter, C. Vigo-Pelfrey, D. Kholodenko, R. Barbour, K. Johnson-Wood, D. Galasko, L. Chang, B. Miller, C. Clark, R. Green, D. Olson, P. Southwick, R. Wolfert, B. Munroe, I. Lieberburg, P. Seubert, D. Schenk, Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease Annals of Neurology. ,vol. 38, pp. 643- 648 ,(1995) , 10.1002/ANA.410380413
Chiara Briani, Jeffrey S Berger, Norman Latov, Antibodies to chondroitin sulfate C: a new detection assay and correlations with neurological diseases Journal of Neuroimmunology. ,vol. 84, pp. 117- 121 ,(1998) , 10.1016/S0165-5728(97)00209-9
F. Hulstaert, K. Blennow, A. Ivanoiu, H. C. Schoonderwaldt, M. Riemenschneider, P. P. D. Deyn, C. Bancher, P. Cras, J. Wiltfang, P. D. Mehta, K. Iqbal, H. Pottel, E. Vanmechelen, H. Vanderstichele, Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF Neurology. ,vol. 52, pp. 1555- 1562 ,(1999) , 10.1212/WNL.52.8.1555
Paul E. Fraser, Audrey A. Darabie, JoAnne McLaurin, Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. implications for drug development. Journal of Biological Chemistry. ,vol. 276, pp. 6412- 6419 ,(2001) , 10.1074/JBC.M008128200
Chiara Briani, Maria Santoro, Norman Latov, Antibodies to chondroitin sulfates A, B, and C: clinico-pathological correlates in neurological diseases Journal of Neuroimmunology. ,vol. 108, pp. 216- 220 ,(2000) , 10.1016/S0165-5728(00)00260-5
Niels Andreasen, Lennart Minthon, Pia Davidsson, Eugeen Vanmechelen, Hugo Vanderstichele, Bengt Winblad, Kaj Blennow, Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice JAMA Neurology. ,vol. 58, pp. 373- 379 ,(2001) , 10.1001/ARCHNEUR.58.3.373
G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E. M. Stadlan, Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology. ,vol. 34, pp. 939- 944 ,(1984) , 10.1212/WNL.34.7.939
Roger M. Nitsch, G. William Rebeck, Meihua Deng, U. Ingrid Richardson, Marsha Tennis, Dale B. Schenk, Carmen Vigo-Pelfrey, Ivan Lieberburg, Richard J. Wurtman, Bradley T. Hyman, John H. Growdon, Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype Annals of Neurology. ,vol. 37, pp. 512- 518 ,(1995) , 10.1002/ANA.410370414
H. M. Fillit, E. Kemeny, V. Luine, M. E. Weksler, J. B. Zabriskie, Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer's type. Journal of Gerontology. ,vol. 42, pp. 180- 184 ,(1987) , 10.1093/GERONJ/42.2.180